Compare Globus Medical Inc. Class A Common Stock (GMED) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Icl Group Ltd — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Icl Group Ltd trades at $4.99 (market cap $6.38B). The key difference: Globus Medical Inc. Class A Common Stock is the larger of the two by market cap, and Icl Group Ltd pays a 4.13% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Icl Group Ltd for 56 Days on average.
| GMED | ICL | |
|---|---|---|
Market Cap | $10.25B | $6.38B |
Volume | 1,108,124 | 1,104,238 |
Sector | Health | Basic Materials |
52-Week High | $96.82 | $6.80 |
52-Week Low | $58.33 | $4.80 |
Typical Hold Time | 0 Days | 56 Days |
Enterprise Value | $9.76B | $9.02B |
Dividend Yield | — | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
ICL trades at $4.99, up 1.01% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $0.12, beating expectations, and maintains a dividend of $0.06. Revenue for 2025 was $7.15B with a net income margin of 3.95%. Valuation metrics show a P/E of 20.75 and P/B of 1.05, while analyst consensus is a Hold with a $6.08 price target.
ICL faces headwinds from fertilizer industry challenges but shows earnings resilience. The stock offers a moderate upside to the consensus target, supported by cost-transformation plans. Risks include input cost pressures and competitive dynamics. Institutional interest is evident with Amundi increasing its stake by 49.7% in Q1 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
